Aequus
(TSX VENTURE: $AQS.V) (OTCQB: $AQSZF) and Scientus Agree to Terms for a Medical
#Cannabis Commercial Supply and Product Development Collaboration
VANCOUVER, BC - August 1, 2017
(Investorideas.com Newswire) Aequus Pharmaceuticals Inc., ("Aequus")
(TSX VENTURE: AQS) (OTCQB: AQSZF), a specialty life sciences company focused on
providing patients with differentiated and enhanced delivery systems for
existing and approved drugs, and Scientus Pharma Inc., ("Scientus"),
a biopharmaceutical company focused on R&D and product commercialization
for extracts and formulations related to medical cannabinoids and their
derivatives, announced today that they have signed a non-binding term sheet on
a collaboration to develop, assess clinical performance, and commercialize a
cannabinoid containing transdermal formulation designed and optimized to
address both acute and chronic treatment of Resistant Epilepsy, and certain
other neurological disorders.
Scientus will be the supplier of
specific cannabinoid extracts and will have an option to co-fund the clinical
development of this program. The parties expect to expand the collaboration to
additional product development programs in the future.
Read
this news in full at http://www.investorideas.com/news/2017/marijuana/08012Aequus.asp
Marijuana /
Hemp Stocks
Like Marijuana Stocks? View our Marijuana / Hemp
Stocks Directory
Join our Group on Linkedin - Marijuana / Hemp
Stocks - News and Trends in Green Investing
Watch the 420 Cannabis Investor video
This
news is published on the Investorideas.com Newswire - a global digital news
source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves risk
and possible loss of investment. This site is currently compensated for news
publication and distribution, social media and marketing, content creation and
more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional
info regarding BC Residents and global Investors: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
No comments:
Post a Comment